Danaher Takes Interest in Life Sciences Firm Catalent

  • In Business
  • 2023-02-06 09:32:42Z
  • By Bloomberg

(Bloomberg) -- Life sciences company Danaher Corp. has expressed takeover interest in contract manufacturer Catalent Inc., according to people familiar with the matter.

Most Read from Bloomberg

  • Strongest Quake in Decades Kills Hundreds in Turkey, Syria

  • China Moves From Contrite to Confrontational Over US Balloon

  • US Moves to Recover Chinese Balloon While Weighing Retaliation

  • US Downs Chinese Balloon, Prompting Protests from Beijing

  • Trump Offers $1 Million Bond to Appeal Clinton Suit Sanctions

The overtures by Danaher in recent months valued Catalent at a significant premium, the people said, asking not to be identified because the matter is private. It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, the people said. A deal isn't imminent, they added.

"As a matter of company policy, Catalent does not comment on market rumors or speculation," a representative said in an emailed statement. A representative for Danaher didn't respond to a request for comment.

Shares in Catalent rose as much as 18.3% in pre-market trading on Monday. The stock closed at $56.05 on Friday, giving the company a market value of about $10 billion.

Catalent, based in Somerset, New Jersey provides delivery technologies and development solutions for drugs, biologics and consumer health products. The manufacturer has gained prominence during the coronavirus pandemic, helping to produce more than a billion Covid-19 vaccines and treatments in partnership with companies including Moderna Inc., Johnson & Johnson and AstraZeneca Plc.

The company's shares more than tripled in the first year of the pandemic but have fallen about 60% since their peak in September 2021.

Danaher has become a life sciences focused company since spinning out its industrial business arm Fortive Corp. in 2016. Shares in the Washington-based company closed at $269.85 Friday, giving it a market value of more than $196 billion.

While Danaher is known in the industry as a serial acquirer, it hasn't announced any major deals since 2021, when it bought Aldevron, a maker of proteins used in vaccines and research, for $9.6 billion.

A deal uniting Danaher and Catalent would be one of the largest transactions this year, in what's been a sleepy market for dealmaking, with volumes down two-thirds globally. That said, US mining powerhouse Newmont Corp. overnight offered to buy Australia's Newcrest Mining Ltd. in a $17 billion deal, which would be the largest deal this year if completed.

--With assistance from Riley Griffin.

(Adds Catalent pre-market share move in fourth paragraph.)

Most Read from Bloomberg Businessweek

  • ChatGPT Gets an MBA

  • A Billionaire's Son Battles a Turbulent WWE Over the Future of Pro Wrestling

  • When Hackers Hobbled Ireland's Hospitals, They Took Themselves Down, Too

  • A Portuguese Manufacturer Aims to Unseat Asia in $5,000 Bikes

  • Drugstore Chains Are Anti-Abortion Groups' Latest Target

©2023 Bloomberg L.P.


More Related News

Putin's Belarus Nuclear Move Puts Him at Odds With China Pledge
  • World
  • 2023-03-27 13:13:04Z

(Bloomberg) -- While Russian President Vladimir Putin's plan to station nuclear weapons in neighboring Belarus is unlikely to change Europe's strategic...

First Citizens Buys Silicon Valley Bank After Run on Lender
First Citizens Buys Silicon Valley Bank After Run on Lender

(Bloomberg) -- First Citizens BancShares Inc. agreed to buy Silicon Valley Bank which was seized by regulators following a run on the lender.Most Read from...

Impax CEO Says Funds Have Run Out of
Impax CEO Says Funds Have Run Out of 'Investible' Green Assets

(Bloomberg) -- Impax Asset Management Group, which runs one of the world's biggest investment portfolios geared toward a low-carbon economy, is warning that ...

US Futures Waver, Bonds Dip With Markets on Edge: Markets Wrap
US Futures Waver, Bonds Dip With Markets on Edge: Markets Wrap

(Bloomberg) -- Early gains for US equity futures evaporated as markets remained on edge, with investors weighing the risk of recession and its impact on...

Morgan Stanley Strategist Says Earnings Are Next Risk to Equities
Morgan Stanley Strategist Says Earnings Are Next Risk to Equities

(Bloomberg) -- Morgan Stanley's Michael Wilson - among the most prominent bearish voices on US stocks - says turmoil in the banking sector has left earnings ...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Business